CRIS · Curis Inc · Executive Compensation
$0.86
+0.03 (+3.53%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In accordance with FASB ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has concluded there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the Condensed Consolidated Financial Statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$1.78M
Shares
2.09M
Volume · Oct 2
100.36K
Avg daily vol (63 sessions)
188.69K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jonathan Zung | Chief Development Officer | $882,415 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Diantha Duvall | Chief Financial Officer | $786,109 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| James E. Dentzer | President and Chief Executive Officer | $3,390,187 |
| James Dentzer | President and Chief Executive Officer | $3,390,187 |
| William E. Steinkrauss | Chief Financial Officer | $1,899,445 |
| Robert Martell | M.D., Ph.D. Head of Research and Development | $1,502,517 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| James Dentzer | President and Chief Executive Officer | $1,672,849 |
| James E. Dentzer | President and Chief Executive Officer | $1,672,849 |
| Robert Martell | M.D., Ph.D. Head of Research and Development | $961,345 |
| William E. Steinkrauss | Chief Financial Officer | $891,755 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| James E. Dentzer | President and Chief Executive Officer | $1,557,773 |
| James Dentzer | President and Chief Executive Officer | $1,557,773 |
| Robert Martell | M.D., Ph.D. Head of Research and Development | $776,494 |
| William E. Steinkrauss | Chief Financial Officer | $690,165 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| James E. Dentzer | President and Chief Executive Officer | $1,964,736 |
| James Dentzer | President and Chief Executive Officer | $1,964,736 |
| Robert Martell | M.D., Ph.D. Head of Research and Development | $940,469 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| James Dentzer | President and Chief Executive Officer | $1,578,961 |
| James E. Dentzer | President and Chief Executive Officer | $1,578,961 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Marc Rubin, M.D. | Class II director | Appointed | 2025-05-22 |
| John A. Hohneker, M.D. | Class II director | Appointed | 2025-05-22 |
| James E. Dentzer | Class I director | Appointed | 2024-05-23 |
| Anne E. Borgman, M.D. | Class I director | Appointed | 2024-05-23 |
| Lori A. Kunkel, M.D. | member of the Board of Directors | Resigned | 2022-09-22 |
| Bill Steinkrauss | Chief Financial Officer | Resigned | 2022-08-04 |
| Diantha Duvall | chief financial officer, treasurer, assistant secretary, principal financial officer and principal accounting officer | Appointed | 2022-08-04 |